These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18798340)

  • 1. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
    Rochon J; Protiva P; Seeff LB; Fontana RJ; Liangpunsakul S; Watkins PB; Davern T; McHutchison JG;
    Hepatology; 2008 Oct; 48(4):1175-83. PubMed ID: 18798340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
    Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
    Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
    Teschke R
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
    Danan G; Teschke R
    Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
    Danan G; Teschke R
    Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
    Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
    Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
    [No Abstract]   [Full Text] [Related]  

  • 7. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.
    Lewis JH; Larrey D; Olsson R; Lee WM; Frison L; Keisu M
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):327-39. PubMed ID: 18793587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
    Teschke R; Eickhoff A; Schulze J; Danan G
    Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
    Teschke R; Danan G
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
    Teschke R; Danan G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM).
    Nin Chau T; Cheung WI; Ngan T; Lin J; Lee KW; Tat Poon W; Leung VK; Mak T; Tse ML;
    Clin Toxicol (Phila); 2011 Jan; 49(1):34-9. PubMed ID: 21114414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.
    Teschke R; Danan G
    Medicines (Basel); 2024 Apr; 11(4):. PubMed ID: 38667507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
    Teschke R; Schulze J; Eickhoff A; Danan G
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.
    Das S; Behera SK; Xavier AS; Velupula S; Dkhar SA; Selvarajan S
    Clin Drug Investig; 2018 Mar; 38(3):211-218. PubMed ID: 29185238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
    Teschke R; Méndez-Sánchez N; Eickhoff A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RUCAM in Drug and Herb Induced Liver Injury: The Update.
    Danan G; Teschke R
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Hepatotoxicity: Causality Assessment.
    Caines A; Moonka D
    Clin Liver Dis; 2020 Feb; 24(1):25-35. PubMed ID: 31753248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
    Teschke R; Danan G
    Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
    [No Abstract]   [Full Text] [Related]  

  • 20. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.
    Ye L; Feng Z; Huang L; Guo C; Wu X; He L; Tan W; Wang Y; Wu X; Hu B; Li T; Yang G; Chengxian G; He Q
    Front Pharmacol; 2021; 12():790108. PubMed ID: 34987403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.